Celgene Evenly Poised

ByEquity Watch: Investment Thesis Celgene Corporation (CELG) is a biopharmaceutical which engages in the discovery and commercialization of therapies for the treatment of cancer and immune-inflammatory diseases. Its primary marketed products at the moment include: Thalomid, Revlimid, Vidaza and Abraxane. The first three products are used in the treatment of blood cancer.

Kevin Wilde submits:

By David Zanoni:If you're looking for an established biotech company with a number of FDA approved drugs already on the market, then Celgene Corporation (CELG) is one to consider. This $28.6 billion large-cap company has five established drugs for the treatment of various cancers currently being marketed. This takes the guesswork out of investing as compared to younger biotech companies which don't yet have any FDA approved drugs on the market.

By Peter Geschek:Few biotech firms can match Celgene's (CELG) recent success: its shares have more than doubled in the past two years. The success can largely be credited to one drug: Revlimid, one of the most successful cancer therapies ever developed.

By Tim Shaw:Celgene Corporation (CELG), a biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases, primarily in the United States and Europe.CELG has a PEG (price earnings growth) ratio of 0.42, and a forward P/E ratio of 11.58. I project the stock will hit $100.00 per share in 2012 or rise approximately 28% from current prices.

Jason Chew submits: During the last decade, Celgene (CELG) has been one of the best performing stocks.

By Peter Geschek: Pomalyst In February the FDA approved Pomalyst (pomalidomide) developed by Celgene (CELG) for the treatment of patients with multiple myeloma whose disease progressed after being treated with other cancer drugs, like Celgene's Revlimid or Johnson & Johnson/Takeda's Velcade.

By Wall Street Trading: By Joseph Morrison Firm Overview